Study of novel NARS2 variants in patient of combined oxidative phosphorylation deficiency 24

Yi Zhang; Xiangyue Zhao; Yufei Xu; Lina Chen; Niu Li; Ruen Yao; Xiumin Wang; Jian Wang; Tingting Yu

doi:10.21037/tp-21-570

Study of novel NARS2 variants in patient of combined oxidative phosphorylation deficiency 24

Transl Pediatr. 2022 Apr;11(4):448-457. doi: 10.21037/tp-21-570.

Authors

Yi Zhang¹, Xiangyue Zhao¹, Yufei Xu¹, Lina Chen¹, Niu Li¹, Ruen Yao¹, Xiumin Wang², Jian Wang¹, Tingting Yu¹

Affiliations

¹ Department of Medical Genetics and Molecular Diagnostic Laboratory, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
² Department of Endocrinology and Metabolism, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Abstract

Background: NARS2 catalyzes the attachment of asparagine amino acids to mitochondrial tRNA^Asn and is critical for efficient mitochondrial protein synthesis. Biallelic variants in NARS2 are associated with combined oxidative phosphorylation deficiency 24 (COXPD24) and autosomal recessive deafness-94.

Methods: Patient information was obtained after recruitment. Genetic tests were performed using whole exome sequencing (WES) and Sanger sequencing. Structure prediction was based on the RaptorX and SWISS-MODEL platforms. The mRNA analysis of paternal variant was performed. Expression levels and dimerization of wild-type (WT) and mutant NARS2 were detected in human embryonic kidney (HEK) 293T cells. Mitochondrial localization of NARS2 variants was determined using immunofluorescence staining.

Results: The patient presented early onset generalized epilepsy, myoclonic seizures, severe bilateral hearing impairment and affected liver and heart. WES identified two compound heterozygous variants in NARS2: c.1141A>G/p.Asn381Asp and c.1290G>C/p.Trp430Cys. In silico analysis predicted that both variants would cause significant and pathogenic changes in secondary structure. NARS2 c.1290G>C is a variant at the first nucleotide of an exon, a location thought to affect mRNA splicing. Although transcriptional experiments did not identify aberrant splicing, we observed a lower proportion of transcripts from the NARS2 c.1290G>C variant. An in vitro experiment showed that both variants impaired NARS2 expression, while mitochondrial localization and dimerization remained unaffected.

Conclusions: The patient was diagnosed with COXPD24 caused by novel NARS2 variations. The cardiac dysfunction is identified for the first time. In vitro study revealed impairment of variants on NARS2 expression. These data enrich our knowledge regarding the phenotypic and genotypic spectra of NARS2.

Keywords: Combined oxidative phosphorylation deficiency 24 (COXPD24); NARS2; epilepsy; hearing impairment; mitochondria.